SNX-5422 + ibrutinib

SNX-5422 + ibrutinib is a combination therapy under investigation primarily for the treatment of chronic lymphocytic leukemia (CLL), especially in patients who have developed resistance to ibrutinib. SNX-5422 is an orally active, synthetic small molecule inhibitor of heat shock protein 90 (Hsp90). It acts as a prodrug for SNX-2112 and leads to degradation of Hsp90 client proteins such as HER2, AKT, and ERK. Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that targets B-cell receptor signaling in CLL. The combination has shown preclinical efficacy in models resistant to BTK inhibition by promoting survival benefit and reducing tumor burden compared to either agent alone. Clinical trials are ongoing to evaluate safety and efficacy in CLL patients with residual disease on ibrutinib monotherapy[1][3][4][5][6].

Other names

SNX 5422SNX5422SNX-5422